Overview

Mechanisms of Refractory Hypertension (Reserpine)

Status:
Completed

Trial end date:
2020-01-31

Target enrollment:

Participant gender:

Summary

The study is deigned to determine if refractory hypertension is attributable to heightened sympathetic tone by quantifying the antihypertensive benefit of reserpine, a sympatholytic agent, in patients failing other classes of antihypertensive agents.

Phase:

Phase 2

Details

Lead Sponsor:

University of Alabama at Birmingham

Treatments:

Reserpine